Company Overview and News
Adobe Systems Inc on Thursday agreed to buy Marketo Inc for $4.75 billion from private equity firm Vista Equity Partners Management, adding heft to its cloud-based digital marketing business.
SAPGF MKTO ADBE SAP OCLCF MSFT MS ORCL
Adobe Systems Inc on Thursday agreed to buy Marketo Inc for US$4.75 billion from private equity firm Vista Equity Partners Management, adding heft to its cloud-based digital marketing business.
MKTO OCLCF MSFT ORCL ADBE
Oracle Corp. (NYSE: ORCL) released its fiscal first-quarter financial results after markets closed on Monday. While the report was not that great, it wasn’t half bad either. Analysts seemed to take a cue from this and their responses to the report were not uniform, with some taking a positive perspective and others still on the fence.
Oracle Corporation (ORCL - Free Report) posted favorable earnings results in its fiscal first quarter. Although the software company posted a marginal revenue miss, on the earnings side, it's been two years since Oracle missed estimates.
CTCAX TXN MDPEB OCLCF MDP ORCL
Oracle Corporation (ORCL - Free Report) reported mixed first-quarter fiscal 2019 results. Non-GAAP earnings of 71 cents per share surpassed the Zacks Consensus Estimate of 68 cents. However, revenues of $9.2 billion marginally lagged the Zacks Consensus Estimate of $9.28 billion.
CY TXN MDPEB OCLCF MDP ORCL AZPN CRM
As required by the UK Listing Authority's Disclosure Guidance and Transparency Rule 4.2, Albion Technology & General VCT PLC today makes public its information relating to the Half-yearly Financial Report (which is unaudited) for the six months to 30 June 2018. This announcement was approved by the Board of Directors on 18 September 2018.
OCLCF LNSTY ORCL
U.S. stock-index futures were slightly higher on Tuesday, though investors continued to monitor the latest development on the trade-policy front, which has recently shown signs of escalating.
GIS V AZO OCLCF MA ORCL
2018-09-18 malaymail - 1
DUBAI, Sept 18 — Saudi Arabia's Public Investment Fund (PIF) has agreed to invest more than US$1 billion (RM4.14 billion) in Lucid Motors, adding to the emerging competition facing US electric vehicle maker Tesla Inc.
OCLCF 9984 SFTBF LCDXW SFTBY ORCL LCDX
Thank you, Victoria. Good afternoon, everyone, and welcome to Oracle’s first quarter fiscal year 2019 earnings conference call. A copy of the press release and financial tables, which includes the GAAP to non-GAAP reconciliation and other financial information, can be viewed and downloaded from our Investor Relations website.
SSREY 530017 FMCKI FMCKJ FREGP N21 ORCL FMCCO FMCCP NBL NOBGF FMCCM FMCCN FMCCK FMCCL FMCCI SIL FMCCJ FMCCG FMCKO LMHA FMCCH FMCKP ZBRA FMCKM LMHB FMCKN FMCKK FMCKL FREJN FREJO FREJP FMCC OCLCF NOBGY NUAN FMCCS LM SSREF
(Reuters) - Oracle Corp (ORCL.N) on Monday reported first-quarter revenue that narrowly missed analysts’ estimates, suggesting that the business software maker was struggling to make inroads in the highly competitive cloud computing market.
OCLCF MSFT ORCL
(Sept 18): Saudi Arabia’s sovereign wealth fund signed an agreement to invest more than $1 billion in aspiring electric-car maker Lucid Motors Inc., months after building a stake in Elon Musk-led Tesla Inc.
7261 BGX MZDAY OCLCF MZDAF BGLF BX SFTBF 9984 SFTBY ORCL BGB
Oracle Corp. shares dropped in the extended session Monday after the enterprise software giant topped Wall Street earnings estimates but fell short on revenue, driven by weaker-than-expected cloud services sales.
(Reuters) - Business software maker Oracle Corp (ORCL.N) on Monday missed revenue estimates for the first quarter, as sales in its cloud services and license support unit disappointed, sending its shares down 5 percent in extended trading.
2018-09-17 247wallst - 1
Oracle Corp. (NYSE: ORCL) released its fiscal first quarter financial results after markets closed on Monday. The company said that it had $0.71 in earnings per share (EPS) and $9.2 billion in revenue, compared with consensus estimates that called for $0.69 in EPS and $9.31 billion in revenue. The same period from last year had $0.62 in EPS and $9.21 billion in revenue.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET